The second generation of the Axio Imager microscope system from Carl Zeiss is setting new standards in materials microscopy. Whether in quality testing and assurance, in materials analysis or the development of future materials - optical quality, performance and comfort are the major benefits of the Axio Imager.
DuPont today opened a photovoltaic (PV) technical center at its China global R+D Center in Shanghai to support material developments for the fast growing crystalline silicon photovoltaic solar energy market. DuPont expects to nearly triple its annual photovoltaic sales to more than $1 billion in 2012.
A delegation from the Russian Nanotechnology Corporation will arrive in the U.S. later on Monday to take part in the Nanotech 2009 conference, the corporation has said.
The delegation, led by Rosnano Director Anatoly Chubais, will hold talks with the world's largest high-tech companies, Intel, Hewlett-Packard and others.
The NanoFabrication Systems Division of NanoInk announced an agreement with the University of Illinois at Urbana-Champaign whereby NanoInk gains access to technology contained in several patents dealing with fabrication of molded tip arrays.
CAP-XX Limited, developer of the supercapacitor-driven BriteFlash Power Architecture, today announced availability of supercapacitor-optimized LED flash drivers from several power management integrated circuit companies to facilitate design of high-power LED flash units for high-resolution camera phones and digital cameras.
Today, American Trim, Ohio State University and General Motors demonstrated, in real time, the actual production of a fuel cell bipolar plate before a group of collaborators and media at American Trim's Research and Development Facility in Lima, Ohio.
Phlo Corporation announced today that one of its affiliates has signed an agreement in principle with S.B. Books, Inc. providing for a license of the Company's Nanoscale Particle Complex Technology to SB for use in products such as liquid chews and energy shots, tongue strips, sprays, and mists.
Axentis Pharma of Zurich, Switzerland announced today that this sought-after designation has been granted to its product candidate Fluidosomes-tobramycin, a therapeutic that will soon be tested in Phase II clinical trials.